DEF 14A: Geron Seeks Stockholder Approval for Equity Plan Amendments at 2025 Annual Meeting

Geron Corporation is asking stockholders to vote on proposals including director elections and amendments to equity incentive plans at its upcoming virtual annual meeting on May 21, 2025.

Summary

• Geron Corporation is holding its 2025 Annual Meeting of Stockholders virtually on May 21, 2025.
• Stockholders will vote on several proposals, including the election of two Class II director nominees, Dawn C. Bir and Elizabeth G. OFarrell, until the 2028 annual meeting.
• The company is seeking approval for amendments to the 2018 Equity Incentive Plan, including increasing the total number of shares issuable by 20,000,000 shares.
• Another proposal involves amending the 2014 Employee Stock Purchase Plan to increase the number of shares issuable by 6,000,000 shares.
• Stockholders will also cast an advisory vote on the compensation of named executive officers.
• The selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, will be up for ratification.
• The board of directors has fixed March 24, 2025, as the record date for determining stockholders entitled to notice of and to vote at the Annual Meeting.
• The company intends to distribute the Notice and the proxy materials on or about April 8, 2025.
• The Board recommends voting FOR all director nominees and FOR Proposals 2, 3, 4, and 5.

Sentiment

Score: 7

Explanation: The document is neutral in tone, providing information about the upcoming annual meeting and proposals for stockholder vote. The sentiment is slightly positive due to the company's progress and future plans.

Positives

• The proposed amendments to the equity incentive plans are intended to attract, retain, and motivate qualified employees, non-employee directors, and consultants.
• The company believes that the issuance of equity awards is a key element underlying its ability to attract, retain and motivate key personnel, non-employee directors and consultants because of the strong competition for highly trained and experienced individuals among biotechnology companies.
• The company's compensation committee actively reviews and assesses its executive compensation program in light of the highly competitive employment environment in the biotechnology industry.

Negatives

• Approval of the Amended 2018 Plan by our stockholders will allow us to continue to attract and retain highly trained and experienced individuals who are critical to our success, through the grant of equity awards at levels determined appropriate by our Board or Compensation Committee.
• The Amended 2018 Plan will also allow us to utilize equity awards as long-term incentives to secure and retain the services of current and future employees, non-employee directors and consultants, consistent with our compensation philosophy and common compensation practice for companies in the biotechnology industry.
• To date, we have relied significantly on equity awards in the form of stock option grants to attract and retain key employees, non-employee directors and consultants, all of whom are critical to our success.

Risks

• The document contains forward-looking statements that involve risks and uncertainties that can cause actual results to differ materially.
• These risks include challenges related to commercializing RYTELO, obtaining regulatory approvals, overcoming delays, and managing clinical, safety, efficacy, technical, and regulatory challenges.
• Other risks include potential adverse events, trial outcomes, manufacturing delays, competition, and compliance with debt and royalty agreements.

Future Outlook

The document discusses the continued development and commercialization of RYTELO, including plans to prepare for and commence commercializing RYTELO in select countries in the European Union beginning in 2026, and expectations regarding the interim and final analyses in the Phase 3 Impact MF clinical trial.

Management Comments

• Thank you for your ongoing support and continued interest in Geron Corporation, By Order of the Board of Directors, Scott A. Samuels, Esq. Executive Vice President, Chief Legal Officer and Secretary

Industry Context

The document highlights the competitive landscape for talent in the biotechnology industry and the importance of equity awards in attracting and retaining key personnel.

Comparison to Industry Standards

• The Compensation Committee believes it is important to be informed as to current compensation practices of comparable publicly-held companies in the life sciences industry, especially to understand the demand and competitiveness for attracting and retaining an individual with each of the non-employee directors specific expertise and experience.
• For 2024, our Compensation Committee engaged Aons Human Capital Solutions practice, a division of Aon plc (Aon), an independent compensation consultant, to provide an analysis of our non-employee director compensation, including an analysis of compensation paid to non-employee directors by companies in our peer group, and an assessment of both the cash and equity compensation and an evaluation of the type of equity being awarded, to ensure alignment with market best practices.

Management Changes

Stakeholder Impact

• Stockholders are asked to vote on key proposals that will impact the company's governance and future.
• Employees may be affected by changes to the equity incentive and stock purchase plans.
• The outcome of the proposals could influence the company's ability to attract and retain talent.

Next Steps

• Stockholders are encouraged to vote on the proposals.
• The company will hold its virtual Annual Meeting on May 21, 2025.
• Geron will prepare for EU launch during 2025 and to launch RYTELO in select EU countries in 2026.

Key Dates

Keywords

proxy statement, annual meeting, equity incentive plan, employee stock purchase plan, executive compensation, directors, Geron Corporation, stockholders